Lipohypertrophy: Does it matter in daily life? A study using a continuous glucose monitoring system

Diabetes, Obesity and Metabolism

Volumn 11, Issue 5, 2009, Pages 460-463

  Overland, Jane ^a   Molyneaux, L ^a,b   Tewari, S ^a   Fatouros, R ^a   Melville, P ^a   Foote, D ^a   Wu, T ^a   Yue, D K ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Continuous blood glucose monitoring; Glycaemic control; Lipohypertrophy

Indexed keywords

GLUCOSE; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC DIET; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIPOHYPERTROPHY; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 65449130419     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00972.x     Document Type: Article

References (10)

1. Alemzadeh R, Loppnow C, Parton E, Kirby M. Glucose sensor evaluation of glycemic instability in pediatric type 1 diabetes mellitus. Diabetes Technol Ther 2003; 5: 167-173.
2. Johansson UB, Amsberg S, Hannerz L et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 2005; 28: 2025-2027.
3. Thow JC, Johnson AB, Marsden S, Taylor R, Home PD. Morphology of palpably abnormal injection sites and effects on absorption of isophane (NPH) insulin. Diabet Med 1990; 7: 795-799.
4. Galloway JA, Root MA, Rathmacher RP, Carmichael MS. A comparison of acid regular and neutral insulin. Responses of normal fasted subjects to varying doses of regular insulin. Diabetes 1973; 22: 471-479.
5. Lauritzen T, Pramming S, Gale EA, Deckert T, Binder C. Absorption of isophane (NPH) insulin and its clinical implications. BMJ 1982; 285: 159-162.
6. Heinmann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid acting insulin analogue insulin aspart. Diabetes Care 1998; 21: 1910-1914.
7. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
8. Metzger M, Leibowitz G, Wainstein J, Glaser B, Raz I. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 2002; 25: 1185-1191.
9. Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in diabetic subjects. Diabet Med 2003; 20: 1012-1015.
10. Rebrin K, Steil GM, van Antwerp WP, Mastrototaro JJ. Subcutaneous glucose predicts plasma glucose independent of insulin: Implications for continuous monitoring. Am J Physiol 1999; 277: E561-E571.